Kinga Maria Tyczyńska

Kinga Maria Tyczyńska

Auto-generated profile, based on publicly available information

Kinga Maria Tyczyńska

Department and Clinic of Rheumatology and Internal Diseases, Wroclaw Medical University, Wroclaw, Poland

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2023 in Rheumatology
Verified
Journal Article
Open access
KTKinga Maria Tyczyńska
Kinga Maria Tyczyńska
HBHanna Augustyniak – Bartosik
Hanna Augustyniak – Bartosik
JŚJerzy Świerkot
Jerzy Świerkot
Renal failure in the course of rheumatoid arthritis (RA) is a consequence of many factors, including drug-induced nephrotoxicity, comorbidities and chronic inflammation. Contemporary treatment strategies have reduced the incidence of renal failure in the population of RA patients. However, it remains a problem for approximately 25% of patients. Therefore, special attention should be paid to the potential need for dosage modifications of administered medications. Many drugs used in the therapy of rheumatic diseases have not been thoroughly studied for their safety in patients with reduced glomerular filtration, resulting in limited data in this area. The establishment of precise, transparent, and consistent dosage recommendations for antirheumatic drugs in chronic kidney dis-ease would significantly facilitate the care of patients with RA. The following review provides a general summary of the available knowledge regarding the dosage of rheumatic medications in renal insufficiency and aims to highlight the need for further research in this area.

30 April 2022 in Toxins
Verified
Journal Article
Open access
PDF file
PKPiotr K Krajewski
Piotr K Krajewski
KTKinga Tyczyńska
Kinga Tyczyńska
KBKlaudia Bardowska
Klaudia Bardowska
POPiotr Olczyk
Piotr Olczyk
MKMagdalena Krajewska
Magdalena Krajewska
Jacek C. SzepietowskiJacek C. Szepietowski
Jacek C. Szepietowski
Itch is the most common symptom of chronic dermatoses. Moreover, itch may be associated with systemic disorders. Chronic kidney disease—associated itch (CKD-aI) may affect up to 20% of renal transplant recipients (RTR). The aim of the study was to assess psychosocial burden of itch in RTR. The study was performed on a group of 129 RTR, out of which 54 (41.9%) experienced itch in the previous 3 days. A specially designed questionnaire assessing anxiety, depression, stigmatization, and quality of life was used. Results: Patients suffering from itch in the previous 3 days achieved significantly higher scores in GAD-7 (p < 0.001), BDI (p < 0.001), HADS total score (p < 0.001), HADS Depression (p = 0.004), and HADS Anxiety (p < 0.001). Severity of itch correlated positively with HADS, stigmatization scale, and GAD-7. Itch in RTR was associated with higher incidence of depression assessed with BDI (OR 3.7). Moreover, higher prevalence of anxiety was found among patients suffering from CKD-aI, assessed with HADS A and GAD-7 (OR 2.7 and OR 4.8, respectively) The results of our study clearly demonstrate that itch among RTR is a significant burden. Higher prevalence of depression and anxiety in this groups indicate the necessity of addressing itch relief as a part of holistic approach to patients after renal transplantation.

Verified
Journal Article
Open access
PDF file
PKPiotr K Krajewski
Piotr K Krajewski
KTKinga Tyczyńska
Kinga Tyczyńska
KBKlaudia Bardowska
Klaudia Bardowska
POPiotr Olczyk
Piotr Olczyk
DNDanuta Nowicka-Suszko
Danuta Nowicka-Suszko
Jacek C. SzepietowskiJacek C. Szepietowski
Jacek C. Szepietowski
Chronic itch (CI) is a common symptom caused by both dermatological and systemic disorders. CI is also a frequent, burdensome symptom among renal transplant recipients (RTR); however, its pathophysiology is not fully understood. The aim of this study was to assess the differences in concentration of IL-31 among itchy RTR. The study was performed on a group of selected 129 RTRs (54 itchy and 75 non-itchy patients). Itch severity was assessed with the use of the numeral rating scale (NRS) and the 4-item itch questionnaire (4IIQ). Every subject had his blood drawn to measure the concentration of IL-31. The results were subsequently compared and correlated. The mean concentration differed significantly between RTR suffering from itch (602.44 ± 534.5 pg/mL), non-itchy RTR (161.49 ± 106.61 pg/mL), and HC (110.33 ± 51.81 pg/mL) (p < 0.001). Post-hoc analysis revealed a statistically significantly increased IL-31 serum concentration in itchy RTR in comparison to the non-itchy RTR group (p < 0.001) and HC (p < 0.001). No significant difference was observed in IL-31 serum levels between non-itchy RTRs and HC. No correlation between IL-31 and itch intensity was found. The results of our study clearly demonstrate the association between IL-31 levels and CI in patients after renal transplantation.

7 June 2025 in Rheumatology International
Verified
Journal Article
Open access
PDF file
KTKinga M. Tyczyńska
Kinga M. Tyczyńska
JŚJerzy Świerkot
Jerzy Świerkot
Seronegative spondyloarthritis (SpA) comprises a heterogeneous group of rheumatic diseases characterized by axial and peripheral joint involvement, as well as extra-articular manifestations, including uveitis, psoriasis, and inflammatory bowel disease. Although renal involvement in SpA is less understood, evidence suggests it may result from disease activity, chronic inflammation, or therapeutic agents. The underlying pathophysiology remains unclear. This systematic review evaluates the prevalence and risk factors associated with renal abnormalities in SpA. A systematic literature search was conducted following the latest Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. Data from 26 studies published between 1980 and 2025 were synthesized. Extracted variables included study author, year and location of publication, sample size, renal assessment parameters, prevalence of renal involvement, presence of control groups, and statistical significance of findings. Renal involvement in SpA, assessed through hematuria, proteinuria, estimated glomerular filtration rate, and International Classification of Diseases codes, showed considerable variability, with prevalence ranging from 0.2 to 77.5%. Nephrolithiasis was also more common among SpA patients, with reported rates between 1.6% and 29.1%. Potential risk factors, including age, disease activity, comorbidities, and HLA-B27 status, were explored, though findings remained inconsistent. This review highlights significant methodological discrepancies among studies assessing renal involvement in SpA. Further research is needed to clarify the renal complications associated with SpA and establish reliable risk factors. PROSPERO Registration: CRD42024579791

12 March 2026 in Virology
Verified
Journal Article
Closed access
JŚJerzy Świerkot
Jerzy Świerkot
KTKinga Maria Tyczyńska
Kinga Maria Tyczyńska
JSJagoda Siemaszko
Jagoda Siemaszko
MMMarta Madej
Marta Madej
ASAgata Sebastian
Agata Sebastian
KBKatarzyna Bogunia-Kubik
Katarzyna Bogunia-Kubik

13 April 2026 in RMD Open
Verified
Journal Article
Open access
PDF file
KTKinga Maria Tyczyńska
Kinga Maria Tyczyńska
PKPiotr Krzysztof Krajewski
Piotr Krzysztof Krajewski
JŚJerzy Świerkot
Jerzy Świerkot
Background: Renal involvement in ankylosing spondylitis (AS) is recognised but understudied, with heterogeneous reports ranging from urinalysis abnormalities to end-stage disease and malignancy. Robust, contemporary and population-level estimates remain lacking. Objective: To quantify the burden and risk of major nephrological outcomes in AS versus matched controls, estimate long-term occurrence, and explore sex-specific differences. Methods: We performed a retrospective, population-based cohort study using the TriNetX Global Collaborative Network of anonymised electronic health records. Adults with AS were compared 1:1 with controls using propensity score matching across demographic factors and relevant comorbidities. The primary renal outcome was chronic kidney disease (CKD), while the secondary outcomes were as follows: acute kidney injury (AKI), dialysis initiation, glomerular diseases, tubulointerstitial nephropathies, proteinuria, haematuria, urolithiasis, nephrological neoplasms and kidney transplantation. Time-to-event analyses used Cox models; robustness was assessed in prespecified sensitivity analyses. Results: After matching, AS was associated with markedly higher hazards across the full spectrum of renal outcomes. The risk of developing CKD (primary outcome) was more than twofold higher in the AS cohort (HR 2.51; 95% CI 2.21 to 2.84). Among secondary outcomes, the highest risk was observed for dialysis initiation (HR 7.58; 95% CI 6.19 to 9.27), followed by AKI (HR 2.18; 95% CI 2.03 to 2.35) and glomerular diseases (HR 2.06; 95% CI 1.71 to 2.49). Associations were consistent across prespecified sensitivity analyses. Conclusions: AS confers a broad, multifactorial increase in renal morbidity. These findings support routine nephrological surveillance within rheumatology pathways. A multidisciplinary approach is warranted to enable earlier detection and mitigate irreversible kidney injury.